Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio presented new Phase 2 data from the VIBRANT trial showing verekitug significantly improved asthma symptom control in patients with CRSwNP and comorbid asthma. The drug reduced the Asthma Control Questionnaire-6 score by 0.9 points versus placebo (p=0.014), exceeding the minimal clinically important change threshold. Verekitug also reduced the need for rescue systemic corticosteroids or surgery by 83% and lowered blood eosinophils by 50% within two weeks.
Key figures
- Drug Name
- verekitug
- Phase Of Trial
- Phase 2
- Acq6 p value
- 0.014
- Acq6 reduction
- -0.9
- Rescue p value
- 0.027
- Trial participants
- 81
- Comorbid asthma pct
- 60
- Rescue reduction pct
- 83
- Eosinophil reduction pct
- 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.